Wednesday , 22 May 2024

Inhibitor Screening and Quantification of Inhibitor Titres by Bethesda Inhibitor Assay in Patients with Coagulation Disorders

Siva Priya S1, Uma A N1*, Lavanya P1, Kavitha K1, RakheeKar2, Sajini Jacob Elizabeth2
1Faculty of Allied Health Sciences, Sri Balaji Vidyapeeth, (Deemed to be University), Puducherry-607402.
2Department of Pathology, JIPMER, Puducherry, India.

A  B  S  T  R A C T
Inhibitor may arise in patients with inherited coagulation disorders or as secondary auto antibodies in previously healthy individuals. This study was conducted over a period of 1 year January 2017 to December 2017 in a large tertiary care centre in Southern India to determine the frequency and the titre of inhibitors among patients with coagulation disorders. A total of 40 patients were enrolled for inhibitor screen of whom 36 were known cases of hemophilia A (33) and B (3), three were new cases of hemophilia and one case of acquired hemophilia. Inhibitor screening was positive in 5 cases of hemophilia A and in the case of acquired hemophilia. In 5 cases the inhibitor was late acting & 1 case the inhibitor was both immediate & late acting for which lupus anticoagulant screening done additionally was negative. The frequency of inhibitor positive cases among inherited hemophilias was 12.5%. Bethesda assay was standardized done for quantification of inhibitor titre in allcases where the inhibitor screening was positive the five cases of hemophilia A and the titres ranged from 12BU to >1024BU. By standardizing Bethesda assay exact titres of inhibitor could be given which would be helpful in further management.
Keywords: Bethesda Assay, Hemophilia, Inhibitor Screening.

Scroll To Top